A clinical study using PARP inhibitors, such as Olaparib and BSI-201, is now ongoing and shows clinical efficacy in the treatment of BRCA1/2-related breast, ovarian, and prostate cancers, as well as sporadic basal-like breast cancers [71]. This evidence concerns the gene BRCA1 and breast cancer.